News
Novo Nordisk, Wegovy and Zepbound
Digest more
COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
Novo Nordisk is hedging and building its way around a global tariff war that may threaten the Wegovy maker’s plans to expand ...
Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...
Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...
8d
Pharmaceutical Technology on MSNNovo Nordisk cuts 2025 outlook due to compounding-hit Wegovy demandNovo Nordisk has cut its sales and profits forecasts for 2025 due to lower demand in the US for blockbuster weight loss and ...
Explore more
Novo Nordisk A/S NVO is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company recently highlighted early data that shows safety and efficacy figures that are similar ...
Novo Nordisk's (NVO) investors are worried its competition ... Lilly's Zepbound overtook Novo's Wegovy as the leading obesity drug, according to the latest prescription data last month.
4h
MarketBeat on MSNIs It Time to Buy the Dip in Novo Nordisk Stock?CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results